A short synthetic peptide fragment of human C2ORF40 has therapeutic potential in breast cancer
Metrics: PDF 1338 views | HTML 1478 views | ?
Chaoyang Li1, Pengju Zhang1, Anli Jiang1, Jian-Hua Mao3 and Guangwei Wei2
1Department of Biochemistry and Molecular Biology, Shandong University School of Medicine, Jinan, Shandong, 250012, P.R. China
2Department of Human Anatomy and Key Laboratory of Experimental Teratology, Ministry of Education, Shandong University School of Medicine, Jinan, Shandong, 250012, P.R. China
3Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
Guangwei Wei, email: firstname.lastname@example.org
Jian-Hua Mao, email: JHMao@lbl.gov
Keywords: C2ORF40 mimic peptide, breast cancer, proliferation, xenograft, mitosis
Received: February 08, 2017 Accepted: March 21, 2017 Published: March 30, 2017
C2ORF40 encodes a secreted protein which is cleaved to generate soluble peptides by proteolytic processing and this process is believed to be necessary for C2ORF40 to exert cell type specific biological activity. Here, we reported a short mimic peptide of human C2ORF40 acts potential therapeutic efficacy in human cancer cells in vitro and in vivo. We synthesized a short peptide of human C2ORF40, named C2ORF40 mimic peptide fragment and assessed its biological function on cancer cell growth, migration and tumorigenesis. Cell growth assay showed that C2ORF40 mimic peptide fragment significantly suppressed cell proliferation of breast and lung cancer cells. Moreover, C2ORF40 mimic peptide fragment significantly inhibited the migration and invasion of breast cancer cells. Furthermore, we showed that this peptide suppressed tumorigenesis in breast tumor xenograft model. Cell cycle assay indicated that the C2ORF40 mimic peptide fragment suppressed the growth of tumor cells through inducing mitotic phase arrest. In conclusion, our results firstly suggested that this short synthetic peptide of human C2ORF40 may be a candidate tumor therapeutic agent.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.